Simple Summary PSMA Therapy has recently become an additional therapeutic option in
advanced prostate cancer. In the present study, the predictive and prognostic value of …

Purpose To evaluate the use of 68 Ga-PSMA PET/CT for monitoring response to 177 Lu-617
PSMA radioligand therapy in patients with metastatic castrate-resistant prostate cancer …

Introduction A new therapeutic option for metastatic castration–resistant prostate cancer
(mCRPC) of heavily pre-treated patients lies in 177 Lu-PSMA-617 radioligand therapy …

Aim Combined 68 Ga-PSMA-617 PET imaging and 177 Lu-PSMA-617 therapy is a precise
targeted theranostic approach for patients with metastatic castration-resistant prostate …

Purpose We analysed quantitative biomarkers derived from both baseline whole-body
imaging and blood serum to identify prognostic markers in patients treated within the …

Earlier studies have mostly identified pre-therapeutic clinical and laboratory parameters for
the prediction of treatment response to [177Lu] Lu-PSMA-617 in metastatic castration …

177Lu-PSMA-617 therapy has shown high prostate-specific antigen (PSA) response rates in
men with metastatic castration-resistant prostate cancer. However, early treatment …

Purpose The first aim of this study was to evaluate 68 Ga-PSMA HBED-CC conjugate 11
positron emission tomography (PSMA PET) parameters for assessment of response to 177 …

Purpose In patients with metastatic castration-resistant prostate cancer (mCRPC) treated
with prostate-specific membrane antigen-targeted radioligand therapy (PSMA-RLT), the …

Simple Summary Prostate-specific membrane antigen (PSMA) is a promising target for both
imaging and radioligand therapies (RLT) for men with prostate cancer. However, not all …